Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer

Key Points

• MAIN FINDING: Anti-b- and t-lymphocyte antibody tifcemalimab combined with toripalimab shows promise in advanced lung cancer.
• KEY EVIDENCE: Progression-free survival (PFS) results were analyzed according to hvem and pd-l1 expression levels.
• APPROACH: The analysis involved previously treated advanced lung cancer patients receiving combination therapy.
• SIGNIFICANCE: Understanding hvem and pd-l1's roles may improve treatment strategies for advanced lung cancer patients.